Biosimilars» burgeoning popularity has fostered some intriguing partnerships as companies try to create new,
innovative biologic therapies, defend their existing products from sales slumps, and develop biosimilars to eat into competitors» branded biologics sales.
Paris, France, April 3, 2018, 5.35 pm CET — GenSight
Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA - PME eligible), a biopharma company focused on discovering and developing
innovative gene
therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced topline results from the REVERSE Phase III clinical trial evaluating the safety and efficacy of a single intravitreal injection of GS010 (rAAV2 / 2 - ND 4) in 37 subjects whose visual loss due to 11778 - ND4 Leber Hereditary Optic Neuropathy (LHON) commenced between 6 and 12 months prior to study treatment.
Through our prescription medicines, vaccines,
biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver
innovative health solutions.